Corporate Directors Forum Names NuVasive, Inc. Board Member as Director of the Year

Published: Sep 20, 2013

Jack Blair, a member of the NuVasive board of directors, was named Director of the Year for Corporate Governance by the Corporate Directors Forum (CDF).

(Click here for details)
Jack Blair, a member of the NuVasive board of directors, was named Director of the Year for Corporate Governance by the Corporate Directors Forum (CDF).

SAN DIEGO, CA--(Marketwired - September 19, 2013) - NuVasive, Inc. (NASDAQ: NUVA), a medical device company focused on developing minimally disruptive surgical products and procedures for the spine, is proud to announce that the Corporate Directors Forum (CDF) named the Company's long-standing board member, Jack Blair, as Director of the Year for Corporate Governance at an awards ceremony on September 18th.

Each year, the CDF honors San Diego's top directors who exhibit outstanding performance. The corporate governance award is bestowed upon a leader that has exceptionally guided the board of directors and executive management of a growing company while maintaining the ethics and integrity of the board.

NuVasive Director Jack Blair said, "Being named Director of the Year is both a humbling and gratifying experience. As a director of NuVasive, I am extremely proud to have played a part in the growth and success of a company that is improving spine patient outcomes globally. The award suggests that my fellow directors and the NuVasive management team appreciate my service, contributions, and commitment to our strategic mission. I am truly honored and wish to thank all of my colleagues for their support."

Jack Blair has been a member of the NuVasive board of directors since August 2001. Throughout his career, Blair has served in various capacities with Smith & Nephew, PLC, and Richards Medical Company. Most recently he was Group President of Smith & Nephew's North and South American and Japanese operations. Until November 2007, Blair served as Chairman of the board of directors of DJO Inc., an orthopaedic company. Blair holds a Bachelor of Arts Degree in Government from Miami University and a Master of Business Administration from the University of California, Los Angeles.

Alex Lukianov, NuVasive Chairman and Chief Executive Officer, said, "Jack Blair has been instrumental in guiding NuVasive in our mission to change spine surgery since he was named to the board of directors in 2001. We are very pleased that Jack's service is being formally recognized, and I look forward to his continued contribution in our drive toward becoming a $1 Billion Start-up™."

Collectively, the NuVasive board of directors has received several prestigious awards, including the CDF Director of the Year and Ernst & Young's Entrepreneur of the Year. Chairman and Chief Executive Officer, Alex Lukianov, was named the 2011 Director of the Year in Corporate Citizenship and received the 2009 Entrepreneur of the Year National Award in Health Sciences. Mr. Lesley Howe was recognized for a 2008 Lifetime Achievement Award in Corporate Governance, and Mr. Peter Farrell, Ph.D., AM, received the 2005 United States Entrepreneur of the Year National Award in Health Sciences.

About the Corporate Directors Forum (CDF)
Corporate Directors Forum is a nonprofit organization located in San Diego. CDF is the largest regional association of corporate directors in the U.S. and offers regular, interactive education programs for directors, officers and business leaders. CDF's purpose is to help directors be better directors through director education and peer-to-peer networking.

For more information on the NuVasive board of directors visit: http://Ez.com/NUVABoard

For NuVasive press materials please visit: http://www.nuvasive.com/about-us/newsroom/

About NuVasive

NuVasive is an innovative global medical device company that is changing spine surgery with minimally disruptive surgical products and procedurally-integrated solutions for the spine. The Company is the 4th largest player in the $8.2 billion global spine market.

NuVasive offers a comprehensive spine portfolio of more than 80 unique products developed to improve spine surgery and patient outcomes. The Company's principal procedural solution is its Maximum Access Surgery, or MAS®, platform for lateral spine fusion. MAS was designed to provide safe, reproducible, and clinically proven outcomes, and is a highly differentiated solution with fully integrated neuromonitoring, customizable exposure, and a broad offering of application-specific implants and fixation devices designed to address a variety of pathologies.

Having pioneered the lateral approach to spine fusion, NuVasive continues to be at the forefront of the spine industry's shift toward less invasive solutions. The Company places a large focus on clinical research and support of the Society of Lateral Access Surgery, or SOLAS®, to expand the body of clinical evidence in support of NuVasive's minimally disruptive solutions and to drive adoption of its techniques. The Company's dedication to innovation continues to spawn game-changing technology such as the PCM® motion preserving disc for the cervical spine, XLIF® Corpectomy for tumor and trauma, and Armada®, which treats adult degenerative scoliosis in a less invasive fashion. The Company has also developed procedural solutions that completely redefine and improve upon traditional procedures like TLIF, PLIF, Posterior Fixation, and ALIF. NuVasive's solutions are increasingly being adopted internationally, as the Company lays the groundwork to continue growing as a global business and to offer industry-leading, Absolutely Responsive customer service to surgeons worldwide. NuVasive is focused on becoming a $1 Billion Start-up™; taking market share by maintaining a commitment to Superior Clinical Outcomes, Speed of Innovation®, and Absolute Responsiveness®.

NuVasive cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive's results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties that could cause actual growth and results to differ materially include, but are not limited to those risks and uncertainties more fully described in NuVasive's press releases and periodic filings with the Securities and Exchange Commission. NuVasive's public filings with the Securities and Exchange Commission are available at www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.